Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120 th AUA Annual Meeting on Sunday, April 27, 2025.

BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced ...

NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update. "Regeneron has one of the most exciting pipelines in the ...

Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une n ...

Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation OXFORD, UK and CLEVELAND, Ohio, US, 29 April 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’) ...

The financing will enable Nova Anchora to advance its lead candidate NvA-011, a recombinant collagen therapy, through IND-enabling studies. The investment underscores the backers’ commitment to ...

deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection Round co-led by Columbus Venture Partners, Panakès ...

In addition, a further 1,220,000 options have been granted under a non-tax advantaged option scheme. These options also have a vesting period of 2 years with one third vesting on grant, one third on ...

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair ...

Basel, 29 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...